Integra LifeSciences Holdings Corporation (IART) Fair Value 2026

IART · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

7.1 /10

32 fundamental signals · 7 models active

Value Trap Risk

LOW (29/100)

Quick Summary — As of 2026-08-27, Integra LifeSciences Holdings Corporation (IART) trades at $16.85, versus a $21.20 median fair value across its 7 active models — 25.8% above the current price. QOC: 7.1/10. Value Trap Risk: 29/100 (LOW). 7/13 models active.

Key Facts

Ticker
IART
Price
$16.85
Quality Score
7.1/10
Value Trap Risk
29/100
Models Active
7/13
Last Updated
Strength: CUCE Ensemble suggests +25.8% upside with 11% confidence
Risk: Majority of models suggest overvaluation

Is Integra LifeSciences Holdings Corporation (IART) Undervalued or Overvalued in 2026?

According to CirclFi’s 7-model valuation engine, Integra LifeSciences Holdings Corporation (IART) appears undervalued as of : the median of 7 independent fair value estimates is $21.20, 25.8% above the current price of $16.85. Estimates range from $2.05 to $49.11. IART scores 7.1/10 on fundamental quality and 29/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. IART’s +25.8% gap is wider than that market norm, and the Medical Devices sector median is -43.5%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Integra LifeSciences Holdings Corporation Stock in 2026? →

What Fair Value Does Each Model Give IART?

7 Intrinsic Value Models vs. Current Price ($16.85)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $14.87 -11.7%
Ensemble · Low Conviction
 $21.20 +25.8%
Intrinsic · High Conviction
 $10.42 -38.2%
Unlock the Full Matrix

Access 4 additional models including PWERM, Regime Cross-Sectional, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 7 Models →

Cancel anytime · No contracts · Instant access

What Is IART's Fair Value Range?

Spread across 7 independent models · $2.05 to $49.11

CirclFi's 7 active models place Integra LifeSciences Holdings Corporation (IART) between $2.05 and $49.11 per share, a spread of 222% of the median. The median of that range — $21.20 — is the fair value CirclFi publishes for IART, against a current price of $16.85.

Low · RCMH-DCFHigh · FTNN
$2.05median $21.20$49.11
Where the range comes from
Most bearish modelRCMH-DCF$2.05
Most bullish modelFTNN Topology$49.11
Model agreement4 bullish · 3 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for IART. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on IART, not a CirclFi price target. How each model works →

What Is Integra LifeSciences Holdings Corporation (IART) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Integra LifeSciences Holdings Corporation's intrinsic value is estimated at a median fair value of $21.20. While the stock appears modestly undervalued at $16.85 (implied upside of +25.8%), our analysis suggests a thinner margin of safety across 4 of 7 bullish models. Notably, FTNN sees the most upside at +191.5% (fair value: $49.11), while RCMH-DCF is the most conservative at -87.8% ($2.05). The spread between these extremes — +279.3% — reveals how different analytical frameworks can reach starkly different conclusions. Among models with highest confidence, EPV lean bearish — adding weight to the bearish side of the thesis.

What Do the Models Say About IART?

7 of 13 models are currently active for IART. Of these, 4 models suggest upside while 3 models suggest overvaluation. Taken together, their median fair value for IART is $21.20 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does IART Rank in Medical Devices?

Among 157 Medical Devices stocks, IART ranks #42 by Quality of Company score. CirclFi's QOC score of 7.1/10 evaluates 32 fundamental signals. A score of 7.1 indicates above-average quality.

See all Most Undervalued Medical Devices Stocks →

The Medical Devices sector introduces analytical considerations specific to healthcare company businesses. For Integra LifeSciences Holdings Corporation, metrics like pipeline depth and stage distribution provide important context that general-purpose valuation models may underweight.

Is IART a Value Trap?

CirclFi's Value Trap algorithm assigns IART a score of 29/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

7 of 13 models are active for Integra LifeSciences Holdings Corporation. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Integra LifeSciences Holdings Corporation scores 7.1 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

The gap between the most bullish and bearish model spans +279.3% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every IART valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across IART's 7 active models, average confidence is 44%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Integra LifeSciences Holdings Corporation Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

10 related Medical Devices stocks with 13-model coverage

LUNGPulmonx CorporationQOC 7.2PHGKoninklijke Philips N.V.QOC 7.1AORTArtivion, Inc.QOC 7.3KIDSOrthoPediatrics Corp.QOC 7.1SGHTSight Sciences, Inc.QOC 7.3NVCRNovoCure LimitedQOC 7.1NSPRInspireMD, Inc.QOC 6.1MDAISpectral AI, Inc.QOC 5.1PODDInsulet CorporationQOC 9.6IRMDIRADIMED CORPORATIONQOC 9.8

Read investment analysis: LUNG · PHG · AORT · KIDS · SGHT · NVCR · NSPR · MDAI · PODD · IRMD

Which Other Stocks Have a Similar Quality Score to IART?

7 companies across all industries closest to IART’s Quality of Company score of 7.1/10.

TIPTTiptree Inc.QOC 7.2SHENShenandoah Telecommunications CompanyQOC 7.1ARCTArcturus Therapeutics Holdings Inc.QOC 7.2GNWGenworth Financial, Inc.QOC 7.1ASANAsana, Inc.QOC 7.2MCHBMechanics BancorpQOC 7.1NVDANVIDIA CorporationQOC 10.0

Read investment analysis: TIPT · SHEN · ARCT · GNW · ASAN · MCHB · NVDA

Where Does IART Sit in CirclFi's Medical Devices Rankings?

IART is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About Integra LifeSciences Holdings Corporation’s Valuation?

What is Integra LifeSciences Holdings Corporation's intrinsic value in 2026?

CirclFi puts Integra LifeSciences Holdings Corporation (IART)'s intrinsic value at $21.20 — the median of 7 independent model estimates as of 2026-08-27, ranging from $2.05 to $49.11. The Quality of Company score is 7.1/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is IART overvalued or undervalued right now?

At $16.85, 4 of 7 active models suggest IART may be undervalued, while 3 indicate potential overvaluation. The median of all 7 fair value estimates is $21.20, 25.8% above the current price of $16.85 — a consensus view that IART is undervalued. The assessment depends on which methodology best fits Integra LifeSciences Holdings Corporation's business model in Medical Devices.

What does a Quality of Company score of 7.1 mean for IART?

Integra LifeSciences Holdings Corporation's QOC of 7.1/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on IART?

CirclFi analyzes IART with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 7 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on IART?

Of the 7 models currently active on IART, FTNN Topology is the most bullish at $49.11 per share, and RCMH-DCF is the most bearish at $2.05. CirclFi's published fair value for IART is the median of that range, $21.20, not either extreme. The gap between the two ends equals 222% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is IART a value trap in 2026?

Integra LifeSciences Holdings Corporation's Value Trap score is 29/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 7-model valuation engine, Integra LifeSciences Holdings Corporation (IART) has a median fair value of $21.20 — 25.8% above the current price of $16.85 — as of 2026-08-27.” Source: circlfi.com/stock/IART/ · Methodology
Primary sources for this IART valuation

Market data for IART as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 7 mathematical frameworks give you clarity on IART.

Unlock All 7 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

4 models hidden for IART Unlock All 7 — $39/mo